


```

8:  geneseqn2003a:*
9:  geneseqn2003b:*
10: geneseqn2003c:*
11: geneseqn2003d:*
12: geneseqn2004a:*
13: geneseqn2004b:*
14: geneseqn2004c:*
15: geneseqn2004d:*
16: geneseqn2004e:*
17: geneseqn2004f:*
18: geneseqn2005a:*
19: geneseqn2005b:*
20: geneseqn2005c:*
21: geneseqn2006a:*
22: geneseqn2006b:*
23: geneseqn2006c:*
24: geneseqn2006d:*
25: geneseqn2007a:*
26: geneseqn2007b:*
27: geneseqn2007c:*
28: geneseqn2007d:*
29: geneseqn2008:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query		DB	ID	Description
		Match	Length			
1	1262	100.0	1262	21	AEG21170	Aeg21170 Human Jab
2	1262	100.0	1262	21	AFS77968	Afs77968 Human Jun
3	1260	99.8	1282	29	AOF63552	Aof63552 Mouse Kip
4	966.8	76.6	1288	18	ADY80674	Ady80674 Human JAB
5	966.8	76.6	1288	18	ADY80675	Ady80675 Human JAB
6	966.8	76.6	1309	18	ADY80676	Ady80676 Human JAB
7	966.8	76.6	1510	18	ADY80669	Ady80669 Human JAB
8	959.4	76.0	1292	10	ADI31651	Adi31651 Human cDN
9	959.4	76.0	1292	12	ADS83718	Ads83718 Human lym
10	959.4	76.0	1292	18	ADY80668	Ady80668 Human JAB
11	948.8	75.2	1277	9	ADF81512	Adf81512 Leukaemia
12	948.8	75.2	1277	12	ACN38816	Acn38816 Tumour-as
13	948.8	75.2	1277	20	AFU76250	Afu76250 Human pro
14	948.8	75.2	1277	20	AFU81485	Afu81485 Human pro
15	948.4	75.2	1287	6	AAD24415	Aad24415 Human RNA
16	936.8	74.2	1433	13	ADP56481	Adp56481 Human bre
17	881.6	69.9	981	2	AAT32620	Aat32620 pACT59 co

18	881.6	69.9	981	3	AAA94275	Aaa94275 Murine T
19	874	69.3	1263	9	ADA53665	Ada53665 Human cod
20	823.2	65.2	949	6	ABS51512	Abs51512 Human cDN
21	797.6	63.2	919	2	AAT32621	Aat32621 pACT74 co
22	797.6	63.2	919	3	AAA94276	Aaa94276 Murine T
23	791.2	62.7	1262	13	ADP56483	Adp56483 Human bre
24	791.2	62.7	1937	13	ADP56482	Adp56482 Human bre
25	790.6	62.6	3479	13	ADR08249	Adr08249 Full leng
26	753.2	59.7	871	6	ABS51518	Abs51518 Human cDN
27	750.2	59.4	868	8	ACA57249	Aca57249 Human adi
28	697.8	55.3	1661	27	ARB60069	Arb60069 DNA fragm
29	674.2	53.4	1059	27	ARB75265	Arb75265 DNA fragm
30	674.2	53.4	1729	6	ABZ78075	Abz78075 Human bre
31	669.8	53.1	777	8	ACA57301	Aca57301 Human adi
32	590.4	46.8	680	8	ACA57034	Aca57034 Human adi
33	570.6	45.2	657	8	ACA57385	Aca57385 Human adi
34	567.6	45.0	654	8	ACA57045	Aca57045 Human adi
35	560.4	44.4	642	6	ABS51593	Abs51593 Human cDN
36	554.4	43.9	636	8	ACA57112	Aca57112 Human adi
37	534.4	42.3	757	27	ARB73520	Arb73520 DNA fragm
38	509.8	40.4	585	6	ABS51610	Abs51610 Human cDN
39	495	39.2	579	19	AEE12148	Aee12148 Hamster c
40	495	39.2	579	19	AEE15790	Aee15790 Hamster S
41	475.6	37.7	1314	13	ADP56484	Adp56484 Human bre
42	475	37.6	562	6	ABK39139	Abk39139 cDNA enco
43	475	37.6	562	8	ACA02654	Aca02654 Lung canc
44	475	37.6	562	8	ACA11468	Aca11468 Human lun
45	475	37.6	562	9	ADH46696	Adh46696 Human lun

ALIGNMENTS

RESULT 1

AEG21170

ID AEG21170 standard; DNA; 1262 BP.

XX

AC AEG21170;

XX

DT 04-MAY-2006 (first entry)

XX

DE Human Jab1 DNA.

XX

KW gene; ds; flavivirus infection; pestivirus infection; infection;

KW Jun-activation binding protein 1; West nile virus infection;

KW neurological disease; temperature disorder; fever;

KW cardiovascular disease; bleeding; jaundice; gastrointestinal disease;

KW metabolic disorder; arthralgia; myalgia; musculoskeletal disease;

KW encephalitis; meningitis; Virucide; Antipyretic; Antiinflammatory;

KW Antiallergic; Hemostatic; Hepatotrophic; apoptosis inhibitor.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 94..1098
 FT /*tag= a
 FT /product= "Jabl"
 XX
 PN WO2006025623-A1.
 XX
 PD 09-MAR-2006.
 XX
 PF 31-AUG-2004; 2004WO-KR002190.
 XX
 PR 31-AUG-2004; 2004WO-KR002190.
 XX
 PA (UYSU-) UNIV SUNGKYUNKWAN.
 XX
 PI Song J, Oh W, Pyo SN, Yang J, Lee H, Lee SR, Sung YH;
 XX
 DR WPI; 2006-204334/21.
 DR P-PSDB; AEG21171.
 XX
 PT New composition comprising a Jab1 (Jun-activation binding protein 1)
 PT protein or the nucleic acid sequence encoding the protein, useful for
 PT treating or preventing a flavivirus or pestivirus infection, e.g. fever,
 PT rash, meningitis.
 XX
 PS Claim 3; SEQ ID NO 1; 72pp; English.
 XX
 CC This invention describes a novel composition for treating or preventing a
 CC flavivirus or pestivirus infection, comprising a Jab1 (Jun-activation
 CC binding protein 1) protein AEG21171 or the nucleic acid sequence encoding
 CC the protein, AEG21170. The invention also describes; a) a method of
 CC screening a compound stimulating expression of a Jab1 protein, comprising
 CC culturing a cell expressing the Jab1 protein, contacting the cultured
 CC cell with candidate compounds for stimulating expression of the Jab1
 CC protein, comparing an expression level of the Jab1 protein with that in a
 CC control not contacted with the candidate compounds and identifying a
 CC compound increasing expression levels of the Jab1 protein and b) a method
 CC of screening a compound stimulating interaction between a Jab1 protein
 CC and a capsid (Cp) protein, comprising culturing a cell transformed with
 CC both a recombinant vector expressing the Jab1 protein and another
 CC recombinant vector expressing the Cp protein of flavivirus or pestivirus,
 CC contacting the cultured cell with candidate compounds for stimulating
 CC interaction between the Jab1 protein and the Cp protein, comparing an
 CC expression level of the Cp protein with that in a control not contacted
 CC with the candidate compounds and identifying a compound reducing

CC expression levels of the Cp protein. The Jab1 nucleic acid AEG21170 can
 CC be incorporated into a recombinant viral vector selected from recombinant
 CC retrovirus, adenovirus, adeno-associated virus and herpes simplex virus.
 CC The composition of the invention is particularly effective for treating
 CC flavivirus infection e.g. West Nile virus which causes fever, rash,
 CC bleeding, jaundice, arthralgia, myalgia, encephalitis or meningitis. This
 CC sequence encodes the human Jab1 protein. The Jab1 protein is found to
 CC interact with the capsid protein of flavivirus and inhibits apoptosis by
 CC accelerating the degradation of the capsid protein.

XX

SQ Sequence 1262 BP; 394 A; 265 C; 302 G; 301 T; 0 U; 0 Other;

Query Match 100.0%; Score 1262; DB 21; Length 1262;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1262; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	CTGGTGGGGAAGGTCCAAAGCCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA	60
Db	1	CTGGTGGGGAAGGTCCAAAGCCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA	60
Qy	61	TTGTGGAGCGACAGCTTCTCCGGTGCCTCGGCCATGGCAGCTTCCGGGAGTGGTATGGCC	120
Db	61	TTGTGGAGCGACAGCTTCTCCGGTGCCTCGGCCATGGCAGCTTCCGGGAGTGGTATGGCC	120
Qy	121	CAGAAAACCTGGGAATTGGCCAACAACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC	180
Db	121	CAGAAAACCTGGGAATTGGCCAACAACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC	180
Qy	181	AAATATGACAAAAACAACAACAAGAAATCCTGGCGGCGAAACCCTGGACTAAGGATCAC	240
Db	181	AAATATGACAAAAACAACAACAAGAAATCCTGGCGGCGAAACCCTGGACTAAGGATCAC	240
Qy	241	CACTACTTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAATGGTGATGCATGCC	300
Db	241	CACTACTTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAATGGTGATGCATGCC	300
Qy	301	AGGTCAGGAGGCAACTTGGAAGTGATGGGTTTGATGCTCGGGAAGTCGACGGCGAGACC	360
Db	301	AGGTCAGGAGGCAACTTGGAAGTGATGGGTTTGATGCTCGGGAAGTCGACGGCGAGACC	360
Qy	361	ATGATCATCATGGACAGTTTCGCTTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT	420
Db	361	ATGATCATCATGGACAGTTTCGCTTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT	420
Qy	421	CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAAACAGGTTGGCCGC	480
Db	421	CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAAACAGGTTGGCCGC	480
Qy	481	CTTGAGAAATGCAATCGGTTGGTATCATAGCCACCCTGGTTATGGCTGCTGGCTCTCCGGG	540

Db	481	CTTGAGAAATGCAATCGGTTGGTATCATAGCCACCCTGGTTATGGCTGCTGGCTCTCCGGG	540	
Qy	541	ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTTCAAGAACCATTGTAGCAGTGGTG	600	
Db	541	ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTTCAAGAACCATTGTAGCAGTGGTG	600	
Qy	601	ATTGATCCAACCGAACAATCTCTGCAGGAAAAGTGAATCTTGGCGCCTTTAGGACATAT	660	
Db	601	ATTGATCCAACCGAACAATCTCTGCAGGAAAAGTGAATCTTGGCGCCTTTAGGACATAT	660	
Qy	661	CCAAAGGGCTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAGACTATCCCACTTAAT	720	
Db	661	CCAAAGGGCTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAGACTATCCCACTTAAT	720	
Qy	721	AAAATAGAAGATTTTGGCGTGCACTGC AAAACAATATTATGCCTTAGAAGTCTCATATTC	780	
Db	721	AAAATAGAAGATTTTGGCGTGCACTGC AAAACAATATTATGCCTTAGAAGTCTCATATTC	780	
Qy	781	AAATCATCTTTGGATCGTAAACTACTTGAGCTTTTGTGGAATAAATACTGGGTGAATACC	840	
Db	781	AAATCATCTTTGGATCGTAAACTACTTGAGCTTTTGTGGAATAAATACTGGGTGAATACC	840	
Qy	841	CTGAGTTCCTCTAGCTTGCTTACTAATGCAGACTACACCACAGGCCAGGTGTTTGATTTG	900	
Db	841	CTGAGTTCCTCTAGCTTGCTTACTAATGCAGACTACACCACAGGCCAGGTGTTTGATTTG	900	
Qy	901	TCTGAGAAAGTTAGAGCAGTCGGAAGCCCAACTGGGACGTGGCAGTTTCATGTTGGGCTTA	960	
Db	901	TCTGAGAAAGTTAGAGCAGTCGGAAGCCCAACTGGGACGTGGCAGTTTCATGTTGGGCTTA	960	
Qy	961	GAAACACATGACCGCAAGTCGGAAGACAAACTTGCCAAAGCTACTAGAGACAGCTGTAAA	1020	
Db	961	GAAACACATGACCGCAAGTCGGAAGACAAACTTGCCAAAGCTACTAGAGACAGCTGTAAA	1020	
Qy	1021	ACCACCATAGAAGCCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAACTGTTTAAT	1080	
Db	1021	ACCACCATAGAAGCCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAACTGTTTAAT	1080	
Qy	1081	CAGATTACGTTGCTTAGTTACCACCAAGTACTTCTCAAAGCTGGTGTGTGGAAGGAAAA	1140	
Db	1081	CAGATTACGTTGCTTAGTTACCACCAAGTACTTCTCAAAGCTGGTGTGTGGAAGGAAAA	1140	
Qy	1141	GAAGCTCAAGTAACACTTTTAAACCCAGTTACCAAACTCAGATTAGAAGACTAAGGTGCT	1200	
Db	1141	GAAGCTCAAGTAACACTTTTAAACCCAGTTACCAAACTCAGATTAGAAGACTAAGGTGCT	1200	
Qy	1201	GTGTGGTGTCTGAGTATTAGCACTGTAATAAACTATCACGTGAAAAAAAAAAAAAAAAA	1260	

Db 1201 GTGTGGTGTCTGAGTATTAGCACTGTAATAAACTATCACGTGAAAAAAAAAAAAAAAAAAAA 1260

Qy 1261 AA 1262

||

Db 1261 AA 1262

RESULT 2

AFS77968

ID AFS77968 standard; DNA; 1262 BP.

XX

AC AFS77968;

XX

DT 14-JUN-2007 (first entry)

XX

DE Human Jun-activation binding protein 1 gene, SEQ ID NO: 1.

XX

KW gene; ds; Jab1; Jun-activation binding protein 1; apoptosis inhibition;

KW flavivirus infection; gene therapy; protein degradation; capsid;

KW pestivirus infection.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT CDS 94..1098

FT /*tag= a

FT /product= "Human Jun-activation binding protein 1"

XX

PN KR2006020531-A.

XX

PD 06-MAR-2006.

XX

PF 31-AUG-2004; 2004KR-00069381.

XX

PR 31-AUG-2004; 2004KR-00069381.

XX

PA (UYSU-) UNIV SUNGKYUNKWAN.

XX

PI Song JW, Oh WK, Sung YH, Lee SR, Lee HW, Pyo SN, Yang JS;

XX

DR WPI; 2006-764085/78.

DR P-PSDB; AFS77969.

XX

PT Composition for treating virus infection diseases comprising jab1

PT inhibiting apoptosis by promotion of decomposition of capsid proteins.

XX

PS Claim 2; SEQ ID NO 1; 26pp; Korean.

XX

CC The invention relates to a composition for treating viral infections

comprising a recombinant vector comprising a Jab1 (Jun-activation binding protein 1) DNA for inhibiting apoptosis by promoting the decomposition of capsid proteins, useful for treating diseases caused by infection by a flavivirus or a pestivirus such as pyrexia, eruption, hemorrhage, jaundice, arthralgia, encephalitis or meningitis. The recombinant vector of the invention is a recombinant virus vector selected from a recombinant retrovirus, adenovirus, adeno-associated virus and Herpes simplex virus. The present sequence encodes the human Jab1 polypeptide of the current invention.

XX

SQ Sequence 1262 BP; 394 A; 265 C; 302 G; 301 T; 0 U; 0 Other;

Query Match 100.0%; Score 1262; DB 21; Length 1262;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1262; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	CTGGTGGGGAAGGTCCAAAGCCGCGACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA	60
Db	1	CTGGTGGGGAAGGTCCAAAGCCGCGACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA	60
Qy	61	TTGTGGAGCGACAGCTTCTCCGGTGCCTCGGCCATGGCAGCTTCCGGGAGTGGTATGGCC	120
Db	61	TTGTGGAGCGACAGCTTCTCCGGTGCCTCGGCCATGGCAGCTTCCGGGAGTGGTATGGCC	120
Qy	121	CAGAAAACCTGGGAATTGGCCAACAACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC	180
Db	121	CAGAAAACCTGGGAATTGGCCAACAACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC	180
Qy	181	AAATATGACAAAAACAACAACAAGAAATCCTGGCGGCGAAACCCTGGACTAAGGATCAC	240
Db	181	AAATATGACAAAAACAACAACAAGAAATCCTGGCGGCGAAACCCTGGACTAAGGATCAC	240
Qy	241	CACTACTTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAATGGTGATGCATGCC	300
Db	241	CACTACTTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAATGGTGATGCATGCC	300
Qy	301	AGGTCAGGAGGCAACTTGAAGTGATGGGTTTGATGCTCGGGAAAGTCGACGGCGAGACC	360
Db	301	AGGTCAGGAGGCAACTTGAAGTGATGGGTTTGATGCTCGGGAAAGTCGACGGCGAGACC	360
Qy	361	ATGATCATCATGGACAGTTTCGCTTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT	420
Db	361	ATGATCATCATGGACAGTTTCGCTTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT	420
Qy	421	CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAAACAGGTTGGCCGC	480
Db	421	CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAAACAGGTTGGCCGC	480
Qy	481	CTTGAGAAATGCAATCGGTTGGTATCATAGCCACCCTGGTTATGGCTGCTGGCTCTCCGGG	540

Db	481	CTTGAGAAATGCAATCGGTTGGTATCATAGCCACCCTGGTTATGGCTGCTGGCTCTCCGGG	540
Qy	541	ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTTCAAGAACCATTGTAGCAGTGGTG	600
Db	541	ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTTCAAGAACCATTGTAGCAGTGGTG	600
Qy	601	ATTGATCCAACCAAGAACATCTCTGCAGGAAAAGTGAATCTTGGCGCCTTTAGGACATAT	660
Db	601	ATTGATCCAACCAAGAACATCTCTGCAGGAAAAGTGAATCTTGGCGCCTTTAGGACATAT	660
Qy	661	CCAAAGGGCTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAGACTATCCCACTTAAT	720
Db	661	CCAAAGGGCTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAGACTATCCCACTTAAT	720
Qy	721	AAAATAGAAGATTTTGGCGTGCACTGCAAACAATATTATGCCTTAGAAGTCTCATATTTT	780
Db	721	AAAATAGAAGATTTTGGCGTGCACTGCAAACAATATTATGCCTTAGAAGTCTCATATTTT	780
Qy	781	AAATCATCTTTGGATCGTAAACTACTTGAGCTTTTGTGGAATAAATACTGGGTGAATACC	840
Db	781	AAATCATCTTTGGATCGTAAACTACTTGAGCTTTTGTGGAATAAATACTGGGTGAATACC	840
Qy	841	CTGAGTTCCTCTAGCTTGCTTACTAATGCAGACTACACCACAGGCCAGGTGTTTGATTTG	900
Db	841	CTGAGTTCCTCTAGCTTGCTTACTAATGCAGACTACACCACAGGCCAGGTGTTTGATTTG	900
Qy	901	TCTGAGAAAGTTAGAGCAGTCGGAAGCCCAACTGGGACGTGGCAGTTTCATGTTGGGCTTA	960
Db	901	TCTGAGAAAGTTAGAGCAGTCGGAAGCCCAACTGGGACGTGGCAGTTTCATGTTGGGCTTA	960
Qy	961	GAAACACATGACCGCAAGTCGGAAGCAAACTTGCCAAAGCTACTAGAGACAGCTGTAAA	1020
Db	961	GAAACACATGACCGCAAGTCGGAAGCAAACTTGCCAAAGCTACTAGAGACAGCTGTAAA	1020
Qy	1021	ACCACCATAGAAGCCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAACTGTTTAAT	1080
Db	1021	ACCACCATAGAAGCCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAACTGTTTAAT	1080
Qy	1081	CAGATTACGTTGCTTAGTTACCACCAAGTACTTCTCAAAGCTGGTGTGTGGAAGGAAAA	1140
Db	1081	CAGATTACGTTGCTTAGTTACCACCAAGTACTTCTCAAAGCTGGTGTGTGGAAGGAAAA	1140
Qy	1141	GAAGCTCAAGTAACACTTTTAACCCAGTTACCAAACTCAGATTAGAAGACTAAGGTGCT	1200
Db	1141	GAAGCTCAAGTAACACTTTTAACCCAGTTACCAAACTCAGATTAGAAGACTAAGGTGCT	1200
Qy	1201	GTGTGGTGTCTGAGTATTAGCACTGTAATAAACTATCACGTGAAAAAAAAAAAAAAAAA	1260

```

Db          1201 GTGTGGTGTCTGAGTATTAGCACTGTAATAAACTATCACGTGAAAAAAAAAAAAAAAAAAAA 1260
Qy          1261 AA 1262
           ||
Db          1261 AA 1262

```

RESULT 3

AOF63552

ID AOF63552 standard; DNA; 1282 BP.

XX

AC AOF63552;

XX

DT 15-MAY-2008 (first entry)

XX

DE Mouse Kipl C-terminus interacting protein-2 coding sequence, SEQ ID 1.

XX

KW drug screening; cancer; leukemia; stem cell;

KW Kipl C-terminus interacting protein-2; Kic2; ds; gene.

XX

OS Mus musculus.

XX

FH Key Location/Qualifiers

FT CDS 116..1120

FT /*tag= a

FT /product= "Kipl C-terminus interacting protein-2"

XX

FN JP2007330205-A.

XX

PD 27-DEC-2007.

XX

PF 16-JUN-2006; 2006JP-00168160.

XX

PR 16-JUN-2006; 2006JP-00168160.

XX

PA (UYNA-) UNIV NARA.

XX

PI Kato J;

XX

DR WPI; 2008-E37671/30.

DR P-PSDB; AOF63555.

DR GENBANK; AF068223.

DR PC:NCBI; gi7380922.

DR PC_ENCPRO:NCBI; gi7380923.

XX

PT Preparation of cancer stem cell useful in screening antileukemic agents,
PT involves raising leukemia spontaneous transgenic non-human animal over
PT expressing Jab1 gene, and obtaining cancer stem cell from raised animal.

XX

PS Example 1; SEQ ID NO 1; 22pp; Japanese.

XX

CC The present invention relates to a method of producing cancer stem cell.
 CC The method involves raising leukemia spontaneous transgenic animal
 CC capable of over expressing Jab1 gene, and obtaining cancer stem cell from
 CC the raised animal. The present invention also provides a method for
 CC screening antileukemic agents comprises contacting the cancer stem cell
 CC with test substance; measuring the Jab1 expression level of cancer stem
 CC cell, stem cell activity or survival rate of cancer stem cell; comparing
 CC the measured parameters with Jab1 expression level, stem cell activity or
 CC survival rate of control (cancer stem cell not contacted with test
 CC substance); and selecting the test substance as therapeutic agent of
 CC leukemia. Also described is: method of evaluating leukemia therapeutic
 CC effect of test drug with respect to target stem cell. The method of the
 CC invention enables the abundant production of cancer stem cells using
 CC transgenic animal and useful in screening therapeutic and/or preventive
 CC agent of leukemia, evaluating drug efficacy and in elucidating cancer
 CC onset mechanism. The present sequence is a mouse Kipl C-terminus
 CC interacting protein-2 (Kic2) coding sequence similar to Homo sapiens Jun
 CC activation domain binding protein (Jab1) of the invention.

CC

CC Revised record issued on 29-JAN-2008 : Enhanced with precomputed
 CC information from BOND.

XX

SQ Sequence 1282 BP; 396 A; 268 C; 311 G; 307 T; 0 U; 0 Other;

Query Match 99.8%; Score 1260; DB 29; Length 1282;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1260; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	CTGGTGGGGAAGGTCCAAAGCCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA	60
Db	23	CTGGTGGGGAAGGTCCAAAGCCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA	82
Qy	61	TTGTGGAGCGACAGCTTCTCCGGTGCTCGGCCATGGCAGCTTCCGGGAGTGGTATGGCC	120
Db	83	TTGTGGAGCGACAGCTTCTCCGGTGCTCGGCCATGGCAGCTTCCGGGAGTGGTATGGCC	142
Qy	121	CAGAAAACCTGGGAATTGGCCAACAACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC	180
Db	143	CAGAAAACCTGGGAATTGGCCAACAACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC	202
Qy	181	AAATATGACAAAAACAACAACAAGAAATCCTGGCGGCGAAACCTGGACTAAGGATCAC	240
Db	203	AAATATGACAAAAACAACAACAAGAAATCCTGGCGGCGAAACCTGGACTAAGGATCAC	262
Qy	241	CACTACTTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAAATGGTGTATGCATGCC	300
Db	263	CACTACTTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAAATGGTGTATGCATGCC	322

Qy	301	AGGTCAGGAGGCCAACTTGAAGTGATGGGTTTGATGCTCGGGAAAGTCGACGGCGAGACC	360
Db	323	AGGTCAGGAGGCCAACTTGAAGTGATGGGTTTGATGCTCGGGAAAGTCGACGGCGAGACC	382
Qy	361	ATGATCATCATGGACAGTTTCGCTTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT	420
Db	383	ATGATCATCATGGACAGTTTCGCTTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT	442
Qy	421	CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAAACAGGTTGGCCGC	480
Db	443	CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAAACAGGTTGGCCGC	502
Qy	481	CTTGAGAAATGCAATCGGTTGGTATCATAGCCACCCTGGTTATGGCTGCTGGCTCTCCGGG	540
Db	503	CTTGAGAAATGCAATCGGTTGGTATCATAGCCACCCTGGTTATGGCTGCTGGCTCTCCGGG	562
Qy	541	ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTTCAAGAACCATTGTAGCAGTGGTG	600
Db	563	ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTTCAAGAACCATTGTAGCAGTGGTG	622
Qy	601	ATTGATCCAACCAGAACAAATCTCTGCAGGAAAAGTGAATCTTGGCGCCTTTAGGACATAT	660
Db	623	ATTGATCCAACCAGAACAAATCTCTGCAGGAAAAGTGAATCTTGGCGCCTTTAGGACATAT	682
Qy	661	CCAAAGGGCTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAGACTATCCCACTTAAT	720
Db	683	CCAAAGGGCTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAGACTATCCCACTTAAT	742
Qy	721	AAAATAGAAAGATTTTGGCGTGCACTGCAAACAATATTATGCCTTAGAAGTCTCATATTTT	780
Db	743	AAAATAGAAAGATTTTGGCGTGCACTGCAAACAATATTATGCCTTAGAAGTCTCATATTTT	802
Qy	781	AAATCATCTTTGGATCGTAAACTACTTGAGCTTTTGTGGAATAAATACTGGGTGAATACC	840
Db	803	AAATCATCTTTGGATCGTAAACTACTTGAGCTTTTGTGGAATAAATACTGGGTGAATACC	862
Qy	841	CTGAGTTCCTCTAGCTTGCTTACTAATGCAGACTACACCACAGGCCAGGTGTTTGATTG	900
Db	863	CTGAGTTCCTCTAGCTTGCTTACTAATGCAGACTACACCACAGGCCAGGTGTTTGATTG	922
Qy	901	TCTGAGAAGTTAGAGCAGTCGGAAGCCCAACTGGGACGTGGCAGTTTCATGTTGGGCTTA	960
Db	923	TCTGAGAAGTTAGAGCAGTCGGAAGCCCAACTGGGACGTGGCAGTTTCATGTTGGGCTTA	982
Qy	961	GAAACACATGACCGCAAGTCGGAAGACAACTTGCCAAAGCTACTAGAGACAGCTGTAAA	1020
Db	983	GAAACACATGACCGCAAGTCGGAAGACAACTTGCCAAAGCTACTAGAGACAGCTGTAAA	1042

Qy	1021	ACCACCATAGAAGCCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAACTGTTTAAT	1080
Db	1043	ACCACCATAGAAGCCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAACTGTTTAAT	1102
Qy	1081	CAGATTAACGTTGCTTAGTTACCACCAAGTACTTCTCAAAGCTGGTGTGTGGAAGGAAAA	1140
Db	1103	CAGATTAACGTTGCTTAGTTACCACCAAGTACTTCTCAAAGCTGGTGTGTGGAAGGAAAA	1162
Qy	1141	GAAGCTCAAGTAACACTTTTAACCCAGTTACCAAACTCAGATTAGAAGACTAAGGTGCT	1200
Db	1163	GAAGCTCAAGTAACACTTTTAACCCAGTTACCAAACTCAGATTAGAAGACTAAGGTGCT	1222
Qy	1201	GTGTGGTGCCTGAGTATTAGCACTGTAATAAACTATCACGTGAAAAAAAAAAAAAAAA	1260
Db	1223	GTGTGGTGCCTGAGTATTAGCACTGTAATAAACTATCACGTGAAAAAAAAAAAAAAAA	1282